Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 7,069 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Neoplasm Clear all
Active, not recruiting Phase 2 Interventional Results available

RCT of CBD for Anxiety in Advanced Breast Cancer

NCT04482244
View directory record Official record
Conditions
Advanced Breast Cancer, Anxiety, CBD
Interventions
Cannabidiol, Placebo
Drug · Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 19, 2026, 10:50 PM EDT
Completed Not applicable Interventional

Arm Function and Quality of Life Following Mastectomy.

NCT00379106
View directory record Official record
Conditions
Breast Cancer
Interventions
Arm Exercises
Procedure
Lead sponsor
University of New Mexico
Other
Eligibility
Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 7, 2010 · Synced Oct 19, 2026, 10:50 PM EDT
Completed Phase 1 Interventional

Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors

NCT01639911
View directory record Official record
Conditions
Malignant Neoplasm of Breast, CNS Malignancy, Malignant Neoplasm of Gastrointestinal Tract, Genitourinary Neoplasms Malignancy and Gender Unspecified, Head and Neck Neoplasms, Melanoma, Malignant Neoplasm of Thorax
Interventions
Alisertib, Pazopanib
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Oct 19, 2026, 10:50 PM EDT
Completed Phase 3 Interventional Results available

Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer

NCT02492711
View directory record Official record
Conditions
HER-2 Positive Breast Cancer, Metastatic Neoplasm
Interventions
Margetuximab, Trastuzumab, Physician's choice of chemotherapy.
Biological · Drug
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
62
States / cities
Chandler, Arizona • Gilbert, Arizona • Goodyear, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 19, 2026, 10:50 PM EDT
Completed No phase listed Observational

Pre-biopsy With Dynamic Acquisitions

NCT00943644
View directory record Official record
Conditions
Breast Cancer
Interventions
Molecular Breast Imaging (MBI), CZT semiconductor detectors
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 16, 2011 · Synced Oct 19, 2026, 10:50 PM EDT
Terminated Phase 1 Interventional Results available

Melatonin Postoperative Sleep Study in Breast Cancer Patients

NCT00506064
View directory record Official record
Conditions
Breast Cancer
Interventions
Melatonin, Placebo, Questionnaire
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
40 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Oct 19, 2026, 10:50 PM EDT
Not listed Phase 2 Interventional

Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer

NCT00491816
View directory record Official record
Conditions
Breast Cancer
Interventions
Erlotinib with neoadjuvant chemotherapy
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 19, 2026, 10:50 PM EDT
Recruiting Not applicable Interventional

NearWave Optical Molecular Monitoring

NCT06744465
View directory record Official record
Conditions
Breast Cancer, HER2-positive Breast Cancer, TNBC - Triple-Negative Breast Cancer, HER2-negative Breast Cancer, Invasive Breast Carcinoma
Interventions
NearWave monitoring
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 19, 2026, 10:50 PM EDT
Completed No phase listed Observational

Effect of Surgery and Radiation Therapy on Tc-99M Sestamibi Uptake Patterns in Molecular Breast Imaging

NCT01027767
View directory record Official record
Conditions
Breast Cancer
Interventions
Molecular Breast Imaging
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 19, 2026, 10:50 PM EDT
Recruiting Not applicable Interventional

Nutrition Awareness Among Women With Non-Metastatic Breast Cancer

NCT07389967
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Metastatic
Interventions
Educational Brochure
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 19, 2026, 10:50 PM EDT
Withdrawn Phase 1 Interventional

Imaging With [11C]Martinostat in Breast Cancer

NCT03721211
View directory record Official record
Conditions
Breast Cancer
Interventions
[11C]Martinostat, MR-PET scanner
Drug · Device
Lead sponsor
Christine Elizabeth Edmonds
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Oct 19, 2026, 10:50 PM EDT
Withdrawn Not applicable Interventional

A Pilot Study of CyberKnife Radiosurgery Delivered to the Partial Breast

NCT00529334
View directory record Official record
Conditions
Breast Cancer
Interventions
CyberKnife Partial Breast Irradiation
Radiation
Lead sponsor
Georgetown University
Other
Eligibility
45 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Oct 19, 2026, 10:50 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer

NCT00905021
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Exemestane, Sutent
Drug
Lead sponsor
Baylor Breast Care Center
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2020 · Synced Oct 19, 2026, 10:50 PM EDT
Withdrawn Phase 2 Interventional

Determining Quality of Life in Breast Cancer Patient After Completing Radiation,Chemotherapy,Surgery or Combination

NCT00712621
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Counseling, Written materials
Behavioral
Lead sponsor
American Scitech International
Other
Eligibility
25 Years to 85 Years · Female only
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Englishtown, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 24, 2009 · Synced Oct 19, 2026, 10:50 PM EDT
Terminated Not applicable Interventional

Study of Fine Art Photographs and Visualization Tapes to Improve Surgical Recovery in Breast Cancer

NCT00179634
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Visualization relaxation, Visual Milieu Enhancement (Fine art photograph)
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 19, 2026, 10:50 PM EDT
Completed Not applicable Interventional Results available

Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer

NCT00343863
View directory record Official record
Conditions
Male Breast Cancer, Nausea and Vomiting, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions
palonosetron hydrochloride, cyclophosphamide, dexamethasone, doxorubicin hydrochloride, quality-of-life assessment, nausea and vomiting therapy, management of therapy complications, ondansetron hydrochloride, survey administration
Drug · Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 19, 2026, 10:50 PM EDT
Not listed Not applicable Interventional

Home-Based Physical Activity Intervention for Taxane-Induced CIPN

NCT04621721
View directory record Official record
Conditions
Breast Cancer Female, Chemotherapy-induced Peripheral Neuropathy, Gait Disorders, Neurologic, Balance; Distorted, Muscle Weakness
Interventions
Gait/balance & resistive exercise
Behavioral
Lead sponsor
University of South Florida
Other
Eligibility
21 Years and older · Female only
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Oct 19, 2026, 10:50 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

NCT06330064
View directory record Official record
Conditions
Recurrent or Metastatic Solid Tumors
Interventions
Ifinatamab deruxtecan
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
Los Angeles, California • Whittier, California • Skokie, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 19, 2026, 10:50 PM EDT
Recruiting Phase 1 Interventional

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

NCT05768932
View directory record Official record
Conditions
Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer, Gastric Cancer, Leukemia Acute Myeloid Leukemia (AML)
Interventions
BAL0891, Tislelizumab, Paclitaxel
Drug · Combination Product
Lead sponsor
SillaJen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
11
States / cities
New Haven, Connecticut • Coral Gables, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 19, 2026, 10:50 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access to ANG1005 for Individual Patients

NCT02755987
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Breast Cancer With Recurrent Brain Metastases, Leptomeningeal Carcinomatosis
Interventions
ANG1005
Drug
Lead sponsor
Angiochem Inc
Industry
Eligibility
18 Years and older · Female only
U.S. locations
2
States / cities
Orange, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 7, 2016 · Synced Oct 19, 2026, 10:50 PM EDT
Completed Phase 2 Interventional

Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer

NCT00166543
View directory record Official record
Conditions
Breast Cancer
Interventions
TAS-108
Drug
Lead sponsor
SRI International
Industry
Eligibility
18 Years and older · Female only
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 18, 2015 · Synced Oct 19, 2026, 10:50 PM EDT
Active, not recruiting Phase 2 Interventional

Evaluating the Safety and Efficacy of a Novel Accelerated Partial Breast Irradiation Regimen

NCT05591547
View directory record Official record
Conditions
Breast Cancer
Interventions
IMRT/VMAT-Based Accelerated Partial Breast Irradiation
Radiation
Lead sponsor
Sanford Health
Other
Eligibility
50 Years and older · Female only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Worthington, Minnesota • Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 19, 2026, 10:50 PM EDT
Withdrawn Phase 1 Interventional

Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

NCT05807126
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Magrolimab, Olaparib
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
Costa Mesa, California • Orange, California • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Oct 19, 2026, 10:50 PM EDT
Terminated Phase 2 Interventional Results available

Effect of Chemotherapy and Radiation Prior to Surgery for Triple Negative Breast Cancer

NCT00603408
View directory record Official record
Conditions
Breast Cancer
Interventions
Cisplatin, Radiation Therapy, Mastectomy
Drug · Radiation · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 19, 2016 · Synced Oct 19, 2026, 10:50 PM EDT